drugset / Trial / NCT00130390

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

NCT00130390

Phase 2 Terminated 98 enrolled Romark Laboratories L.C.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy and safety of nitazoxanide compared to a placebo in reducing the signs and symptoms of mild to moderate active Crohn's disease in adults.

Timeline

Start
2005-08
Primary completion
2007-12
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 500 mg Oral

Indications